Anti-endothelial cell antibodies in patients with cerebral small vessel disease

Current Neurovascular Research

Volumn 9, Issue 4, 2012, Pages 296-301

  Kimura, Akio ^a   Sakurai, Takeo ^a   Yamada, Megumi ^a   Koumura, Akihiro ^a   Hayashi, Yuichi ^a   Tanaka, Yuji ^a   Hozumi, Isao ^a   Ohtaki, Hirofumi ^a   Chousa, Mitsuhiro ^a   Takemura, Masao ^a   Seishima, Mitsuru ^a   Inuzuka, Takashi ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibody; Endothelial cells; Tropomyosin; White matter hyperintensity

Indexed keywords

ALPHA ENOLASE; ENDOTHELIAL CELL ANTIBODY; LIPOCORTIN 2; TROPOMYOSIN ALPHA 4; UNCLASSIFIED DRUG; VIMENTIN;

AGED; ARTICLE; BRAIN; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; SERUM; TANDEM MASS SPECTROMETRY;

EID: 84870433281     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/156720212803530726     Document Type: Article

References (38)

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9(7):689-701.
2. Longstreth WT, Arnold AM, Beauchamp NJ, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2005;36(1):56-61. (Pubitemid 40054175)
3. Silbert LC, Nelson C, Howieson DB, Moore MM, Kaye JA. Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline. Neurology 2008;71(2):108-13.
4. Steffens DC, Bosworth HB, Provenzale JM, MacFall JR. Subcortical white matter lesions and functional impairment in geriatric depression. Depress Anxiety 2002;15(1):23-8. (Pubitemid 34160262)
5. Vermeer SE, Hollander M, van Dijk EJ, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003;34(5):1126-9. (Pubitemid 36547501)
6. Hassan A, Hunt BJ, O'Sullivan M, et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 2003;126(Pt 2):423-32.
7. Knottnerus IL, Ten Cate H, Lodder J, Kessels F, van Oostenbrugge RJ. Endothelial dysfunction in lacunar stroke: a systematic review. Cerebrovasc Dis 2009;27(5):519-26.
8. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, Schmidt R. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke 2005;36(7):1410-4. (Pubitemid 40967503)
9. Alex M, Baron EK, Goldenberg S, Blumenthal HT. An autopsy study of cerebrovascular accident in diabetes mellitus. Circulation 1962;25:663-73.
10. Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol 2002;1(7):426-36. (Pubitemid 37159153)
11. Hiroki M, Miyashita K. Linear hyperintensity objects on magnetic resonance imaging related to hypertension. Cerebrovasc Dis 2001;11(3):164-8. (Pubitemid 32304626)
12. Khan U, Porteous L, Hassan A, Markus HS. Risk factor profile of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry 2007;78(7):702-6. (Pubitemid 46998839)
13. Manolio TA, Kronmal RA, Burke GL, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. Stroke 1994;25(2):318-27. (Pubitemid 24047252)
14. Rouhl RP, van Oostenbrugge RJ, Theunissen RO, et al. Autoantibodies against oxidized low-density lipoprotein in cerebral small vessel disease. Stroke 2010;41(11):2687-9.
15. Alard JE, Hillion S, Guillevin L, et al. Autoantibodies to endothelial cell surface ATP synthase, the endogenous receptor for hsp60, might play a pathogenic role in vasculatides. PLoS One 2011;6(2):e14654.
16. Praprotnik S, Blank M, Levy Y, et al. Anti-endothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells. Int Immunol 2001;13(2):203-10. (Pubitemid 32123954)
17. Ronda N, Leonardi S, Orlandini G, et al. Natural anti-endothelial cell antibodies (AECA). J Autoimmun 1999;13(1):121-7. (Pubitemid 29367015)
18. Servettaz A, Guilpain P, Camoin L, et al. Identification of target antigens of antiendothelial cell antibodies in healthy individuals: A proteomic approach. Proteomics 2008;8(5):1000-8. (Pubitemid 351441439)
19. Servettaz A, Guilpain P, Tamas N, Kaveri SV, Camoin L, Mouthon L. Natural anti-endothelial cell antibodies. Autoimmun Rev 2008;7(6):426-30.
20. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23-30. (Pubitemid 30479402)
21. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149(2):351-6. (Pubitemid 17104996)
22. Schmidt R, Fazekas F, Kapeller P, Schmidt H, Hartung HP. MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. Neurology 1999;53(1):132-9. (Pubitemid 29329661)
23. Toda T, Kimura N. Standardization of protocol for Immobiline 2-D PAGE and construction of 2-D PAGE protein database on World Wide Web home page. Jpn J Electrophor 1997;41(1):13-20.
24. Lin JJ, Warren KS, Wamboldt DD, Wang T, Lin JL. Tropomyosin isoforms in nonmuscle cells. Int Rev Cytol 1997;170:1-38. (Pubitemid 27056583)
25. Perry SV. Vertebrate tropomyosin: distribution, properties and function. J Muscle Res Cell Motil 2001;22(1):5-49. (Pubitemid 32831636)
26. Pittenger MF, Kazzaz JA, Helfman DM. Functional properties of non-muscle tropomyosin isoforms. Curr Opin Cell Biol 1994;6(1):96-104. (Pubitemid 24048701)
27. Wang CL, Coluccio LM. New insights into the regulation of the actin cytoskeleton by tropomyosin. Int Rev Cell Mol Biol 2010;281:91-128.
28. Doñate F, McCrae K, Shaw DE, Mazar AP. Extracellular tropomyosin: a novel common pathway target for anti-angiogenic therapy. Curr Cancer Drug Targets 2004;4(7):543-53. (Pubitemid 39536375)
29. Zhang JC, Donate F, Qi X, et al. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci U S A 2002;99(19):12224-9.
30. Guan X, Juarez JC, Qi X, et al. Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb Haemost 2004;92(2):403-12. (Pubitemid 39172321)
31. Xu B, deWaal RM, Mor-Vaknin N, Hibbard C, Markovitz DM, Kahn ML. The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. Mol Cell Biol 2004;24(20):9198-206. (Pubitemid 39313921)
32. Glaser-Gabay L, Raiter A, Battler A, Hardy B. Endothelial cell surface vimentin binding peptide induces angiogenesis under hypoxic/ischemic conditions. Microvasc Res 2011;82(3):221-6.
33. Terrier B, Degand N, Guilpain P, Servettaz A, Guillevin L, Mouthon L. Alpha-enolase: a target of antibodies in infectious and autoimmune diseases. Autoimmun Rev 2007;6(3):176-82. (Pubitemid 46201958)
34. Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 2001;58(7):902-20. (Pubitemid 32652817)
35. Lee KH, Chung HS, Kim HS, et al. Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet's disease. Arthritis Rheum 2003;48(7):2025-35. (Pubitemid 36828698)
36. Yang HB, Zheng WJ, Zhang X, Tang FL. Induction of endothelial cell apoptosis by anti-alpha-enolase antibody. Chin Med Sci J 2011;26(3):152-7.
37. Salle V, Mazière JC, Smail A, et al. Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome. J Clin Immunol 2008;28(4):291-7.
38. Cesarman-Maus G, Ríos-Luna NP, Deora AB, et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006;107(11):4375-82. (Pubitemid 43801363)